<DOC>
	<DOCNO>NCT02650648</DOCNO>
	<brief_summary>This phase I study . The purpose study see safe feasible give participant cyclophosphamide ( type chemotherapy ) , natural killer ( NK ) cell , antibody call Hu3F8 treatment neuroblastoma . NK cell type white blood cell . Funding Source- FDA OOPD</brief_summary>
	<brief_title>Humanized Anti-GD2 Antibody Hu3F8 Allogeneic Natural Killer Cells High-Risk Neuroblastoma</brief_title>
	<detailed_description />
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<criteria>Diagnosis NB define international criterion , .e. , histopathology ( confirm MSKCC Department Pathology ) bone marrow metastases plus high urine catecholamine level . Highrisk NB define riskrelated treatment guidelines1 International NB Staging System , i.e. , stage 4 ( age ) without ( &gt; 365 day age ) MYCN amplification , MYCNamplified stage 3 ( unresectable ; age ) , MYCNamplified stage 4S . Patients must history tumor progression persistent disease failure achieve complete response follow standard therapy . Patients must evaluable ( microscopic marrow metastasis , elevate tumor marker , positive MIBG PET scan ) measurable ( CT , MRI ) disease document completion prior systemic therapy . Disease stag approximately within one month treatment Prior treatment murine hu3F8 allow . Patients prior m3F8 , hu3F8 , ch14.18 hu14.18 treatment must HAHA antibody titer â‰¤1300 Elisa units/ml . Human antimouse antibody positivity allow . Eligible NK donor Children adult eligible Signed informed consent indicate awareness investigational nature program . Donor Inclusion Criteria Donor bloodrelated HLAhaploidentical recipient . Donor undergone serologic test transmissible disease per blood banking guideline organ tissue donor . Tests include limited : Hepatitis B Surface Antigen , Hepatitis B Surface Antibody , Hepatitis B Core Antibody , Hepatitis C antibody , EpsteinBarr Virus Antibody , HIV , HTLV I II , Varicella Zoster ( Herpes Zoster ) , Herpes Simplex Antibody , Cytomegalovirus Antibodies , Syphilis ( RPR profile ) adolescents adult , measles pediatric patient , West Nile Virus , Chagas screen , Toxoplasma antibody . Donor must able undergo leukopheresis total volume 1015 liter . There age restriction donor . Patients CR/VGPR disease Existing severe major organ dysfunction , i.e. , renal , cardiac , hepatic , neurologic , pulmonary , gastrointestinal toxicity &gt; grade 3 except hear loss , alopecia , anorexia , nausea , hyperbilirubinemia hypomagnesemia TPN , may grade 3 ANC &gt; 500/uL Platelet count &gt; 75K/uL . History allergy mouse protein Active lifethreatening infection Inability comply protocol requirement Women pregnant breastfeed Donor Cardiac risk factor preclude ability undergo leukopheresis Concurrent malignancy autoimmune disease Donor pregnant</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Humanized Anti-GD2 Antibody Hu3F8</keyword>
	<keyword>Allogeneic Natural Killer Cells</keyword>
	<keyword>rIL-2</keyword>
	<keyword>15-272</keyword>
</DOC>